Cinacalcet Hydrochloride

CHEMBL1200776 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

393.9 g/mol

LogP

—

Phase

4

The hydrochloride salt form of cinacalcet is the standard oral preparation used in patients with chronic kidney disease on dialysis to control secondary hyperparathyroidism. It should be taken with food to maximize absorption. Nausea and vomiting are common initial side effects that often improve with dose titration.

Moleküler Ağırlık

393,9000 g/mol

TPSA

12,00 Å²

Terapötik Alanlar

Osteoporosis Chronic Kidney Disease Nephrology Cardiovascular Disease Prostate Cancer

Etki Mekanizması

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12.Cl

InChI

InChI=1S/C22H22F3N.ClH/c1-16(20-13-5-10-18-9-2-3-12-21(18)20)26-14-6-8-17-7-4-11-19(15-17)22(23,24)25;/h2-5,7,9-13,15-16,26H,6,8,14H2,1H3;1H/t16-;/m1./s1

Molecular Formula

C22H23ClF3N

HBD / HBA

2 / 4

Döndürülebilir Bağlar

6

Ağır Atomlar

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The hydrochloride salt form of cinacalcet is the standard oral preparation used in patients with chronic kidney disease on dialysis to control secondary hyperparathyroidism. It should be taken with food to maximize absorption. Nausea and vomiting are common initial side effects that often improve with dose titration.

Mimics or modulates parathyroid hormone activity to stimulate osteoblast-mediated bone formation, increasing bone mineral density and reducing fracture risk.

Yes, Cinacalcet Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200776. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 156418. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Cinacalcet Hydrochloride PillFYI'da

Yapı

Hızlı Veriler

Formül: C22H23ClF3N
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.

Cinacalcet Hydrochloride

Terapötik Alanlar

Etki Mekanizması

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

Cite this structure

Embed this structure

No targets recorded

No interactions recorded

No side effects recorded

Sıkça Sorulan Sorular

References & Data Sources

Embed This Widget